Q4 2023 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2024-02-14 · accession 0001214659-24-002612
$901.7M
Reported value
29
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $86.0M | 9.54% | 2,109,584 | Common | SOLE |
| 45720L107 | INBXUSD | INHIBRX,INC | $66.5M | 7.38% | 1,750,387 | Common | SOLE |
| 45114M109 | — | ICOSAVAX INC | $58.4M | 6.47% | 3,703,704 | Common | SOLE |
| 037326105 | ANTX | AN2 Therapeutics, Inc. | $54.9M | 6.09% | 2,678,209 | Common | SOLE |
| 75525N107 | — | RAYZEBIO, INC. | $54.1M | 6.00% | 869,908 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $49.8M | 5.52% | 2,201,274 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $49.3M | 5.47% | 23,375,839 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC. | $47.0M | 5.21% | 10,000,000 | Common | SOLE |
| 38406L103 | — | GRACELL BIOTECHNOLOGIES INC. | $45.3M | 5.03% | 4,514,786 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $41.6M | 4.62% | 179,917 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS, INC | $41.6M | 4.61% | 3,395,495 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $36.6M | 4.05% | 2,104,875 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $33.8M | 3.74% | 3,858,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $33.1M | 3.67% | 5,631,042 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $27.5M | 3.06% | 1,989,103 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $26.4M | 2.93% | 1,007,902 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS, INC. | $23.1M | 2.57% | 1,142,857 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS, INC | $21.9M | 2.43% | 1,650,150 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $20.5M | 2.27% | 1,423,642 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $16.2M | 1.80% | 2,040,816 | Common | SOLE |
| 92840H202 | — | VISTAGEN THERAPEUTICS INC | $13.8M | 1.53% | 2,676,580 | Common | SOLE |
| 00370M103 | ABVX | Abivax SA | $11.8M | 1.31% | 1,100,000 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO, INC | $11.1M | 1.23% | 486,795 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $8.8M | 0.98% | 584,955 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $7.4M | 0.82% | 717,654 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS, INC. | $7.2M | 0.80% | 1,276,574 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES, INC. | $5.2M | 0.57% | 2,912,861 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES, INC | $2.0M | 0.22% | 815,724 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $814,540 | 0.09% | 267,941 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.